Waleed H. Hassanein Sells 12,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $7,044,932.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $91.82 on Friday. The firm’s fifty day simple moving average is $82.77 and its 200-day simple moving average is $72.15. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The stock has a market cap of $3.00 billion, a PE ratio of -119.25 and a beta of 1.99. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $99.63.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. The firm’s revenue was up 158.6% on a year-over-year basis. Analysts expect that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on TMDX shares. JPMorgan Chase & Co. lifted their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Oppenheimer lifted their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. Piper Sandler began coverage on shares of TransMedics Group in a report on Thursday, March 28th. They set an “overweight” rating and a $95.00 price target for the company. Finally, Morgan Stanley raised their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $102.00.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently modified their holdings of the company. Park Avenue Securities LLC raised its holdings in TransMedics Group by 3.4% during the first quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock worth $841,000 after purchasing an additional 372 shares during the last quarter. HighPoint Advisor Group LLC acquired a new stake in TransMedics Group in the fourth quarter valued at $603,000. Vanguard Group Inc. increased its position in shares of TransMedics Group by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after buying an additional 50,673 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of TransMedics Group by 10.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock worth $31,358,000 after buying an additional 38,951 shares during the last quarter. Finally, Eventide Asset Management LLC boosted its position in shares of TransMedics Group by 7.4% in the 4th quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock worth $78,475,000 after buying an additional 68,884 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.